[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-368999-en":59,"doc-seo-368999-105":100},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":72,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":73,"language":74,"language_code":75,"site_id":76,"html_lang":75,"table_of_contents":77,"faqs":78,"seo_title":79,"seo_description":66,"update_tm":80,"read_time":81,"preview_page_count":19,"preview_urls":82},368999,5909893218464,"dhado","https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Liquid Biopsy and Circulating Biomarkers in Head and Neck Cancer - Advancing Non-Invasive Detection and Tailored Management","Head and neck squamous cell carcinoma (HNSCC) is a major malignancy with poor outcomes driven by delayed diagnosis and biological heterogeneity. Liquid biopsy offers minimally invasive tumor characterization and longitudinal monitoring using circulating biomarkers including ctDNA, CTCs, cfRNA, miRNAs, extracellular vesicles, and viral nucleic acids. Evidence from narrative review synthesis highlights strong performance of ctDNA and viral ctDNA for minimal residual disease, early relapse detection, and prognosis, while emerging markers need further standardization.","Review  \nLiquid Biopsy and Circulating Biomarkers in Head and Neck Cancer: Advancing Non-Invasive Detection and Tailored Management  \nIlaria Morelli 1,2, *, Chiara Ghirardini 1,3, Laura Faccani 1,3, Claudia Casanova 1, Ignacio Javier Fernandez 2,4 and Stefano Tamberi 1,2  \nAcademic Editors: Yafeng Ma and Kevin Spring  \nReceived: 8 November 2025  \nRevised: 4 December 2025  \nAccepted: 10 December 2025  \nPublished: 12 December 2025  \nCitation: Morelli, I.; Ghirardini, C.; Faccani, L.; Casanova, C.; Fernandez, I.J.; Tamberi, S. Liquid Biopsy and Circulating Biomarkers in Head and Neck Cancer: Advancing NonInvasive Detection and Tailored Management. Cancers 2025, 17, 3974 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)cancers17243974  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Oncology Unit, Santa Maria delle Croci Hospital-AUSL Romagna, 48121 Ravenna, Italy; [chiara.ghirardini@auslromagna.it](chiara.ghirardini@auslromagna.it) (C.G.); [laura.faccani2@auslromagna.it](laura.faccani2@auslromagna.it) (L.F.); [claudia.casanova@auslromagna.it](claudia.casanova@auslromagna.it) (C.C.); stefano.tamberi@auslromagna.it or [stefano.tamberi@unibo.it](stefano.tamberi@unibo.it) (S.T.)  \n2 Department of Medical Sciences (DIMEC), University of Bologna, 40126 Bologna, Italy; [ignacio.fernandez4@unibo.it](ignacio.fernandez4@unibo.it)  \n3 Oncology Unit, University Hospital of Ferrara, 44124 Ferrara, Italy  \n4 Department of Otolaryngology Head and Neck Surgery, Santa Maria delle Croci Hospital-AUSL della Romagna, 48121 Ravenna, Italy  \n* Correspondence: [ilaria.morelli2@auslromagna.it](ilaria.morelli2@auslromagna.it)  \nSimple Summary  \nHead and neck squamous cell carcinoma (HNSCC) is a common and aggressive cancer with poor survival rates due to late diagnosis and biological heterogeneity. Liquid biopsy has emerged as a minimally invasive method to detect and monitor tumors using circulating biomarkers such as ctDNA, CTCs, cfRNA, miRNAs, extracellular vesicles and viral DNA. ctDNA, particularly viral ctDNA in HPV-positive cases, shows high sensitivity for detecting minimal residual disease and early relapse, often outperforming conventional imaging. Emerging biomarkers like TP53 mutations and methylation signatures hold promise for HPV-negative tumors. Despite technological advances in ddPCR and NGS, challenges remain in standardization and clinical validation. Integrating liquid biopsy into routine care could improve early detection, prognostic accuracy, and personalized treatment strategies.  \nAbstract  \nBackground: Head and neck squamous cell carcinoma (HNSCC) ranks as the sixth most common malignancy worldwide, with approximately 600.000 new cases diagnosed annually. Despite improvements in multimodal therapy, survival rates remain unsatisfactory due to delayed diagnosis, lack of population screening and heterogeneous disease biology. In recent years, liquid biopsy has emerged as a promising, minimally invasive approach for tumor characterization and disease monitoring, with potential applications in early detection, prognosis, and treatment guidance. Methods: A comprehensive narrative review was performed through PubMed, Scopus and Embase databases to identify studies investigating circulating biomarkers in HNSCC. Eligible articles published in English up to 2025 were analyzed, focusing on diagnostic accuracy, prognostic value and predictive relevance of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), cell-free RNA (cfRNA), microRNAs (miRNAs), extracellular vesicles (EVs) and viral nucleic acids. Results: Current evidence shows that ctDNA and viral ctDNA are the most clinically mature biomarkers, demonst","cbCaidvllEhiFr1x","https://ap.wps.com/l/cbCaidvllEhiFr1x","pdf",655723,12,33,"English","en",105,"# Introduction\n## The Unmet Need for Biomarkers in Head and Neck Oncology\n# Methods\n# Results\n# Conclusions","[{\"question\":\"What is liquid biopsy used for in head and neck cancer?\",\"answer\":\"Liquid biopsy is used to detect and monitor tumors through circulating biomarkers such as ctDNA, CTCs, cfRNA, miRNAs, extracellular vesicles, and viral nucleic acids, supporting applications in early detection, prognosis, and treatment guidance.\"},{\"question\":\"Which biomarkers show the most clinical maturity according to the review?\",\"answer\":\"The review indicates that ctDNA and viral ctDNA are the most clinically mature biomarkers, with high sensitivity for minimal residual disease detection and the capacity to anticipate recurrence before imaging.\"},{\"question\":\"What are the main barriers to routine clinical adoption?\",\"answer\":\"Key barriers include heterogeneity among studies, lack of assay standardization, and variable sensitivity thresholds, which limit widespread implementation until clinical validation and standardized protocols are established.\"}]","Liquid Biopsy and Circulating Biomarkers in Head and Neck Cancer - Advancing Non-Invasive Detection and Tailored Management | PDF",1790180104,83,[83,87,91,96],{"page_no":8,"url":84,"width":85,"height":86},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9be2b41f41c321ae487d8471e4be0f57.webp",983,1390,{"page_no":14,"url":88,"width":89,"height":90},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6a187d2b4b7c1ed8ea5c4982c9b7c924.webp",982,1388,{"page_no":92,"url":93,"width":94,"height":95},3,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6342b54ae51a1b3483ad4fef895a98d.webp",981,1387,{"page_no":19,"url":97,"width":98,"height":99},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e8400c9228f72b7b3cf32ea95d88454a.webp",980,1385,{"code":4,"msg":101,"data":102},"ok",{"site_id":76,"language":75,"slug":103,"title":65,"keywords":104,"description":66,"schema_data":105,"social_meta":158,"head_meta":160,"extra_data":162,"updated_unix":163},"liquid-biopsy-and-circulating-biomarkers-in-head-and-neck-cancer-advancing-non-invasive-detection-and-tailored-management","",{"@graph":106,"@context":157},[107,120,140],{"@type":108,"itemListElement":109},"BreadcrumbList",[110,114,116,118],{"item":111,"name":112,"@type":113,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":115,"name":9,"@type":113,"position":14},"https://docshare.wps.com/document/",{"item":117,"name":40,"@type":113,"position":92},"https://docshare.wps.com/document/research-report/",{"item":119,"name":65,"@type":113,"position":19},"https://docshare.wps.com/document/liquid-biopsy-and-circulating-biomarkers-in-head-and-neck-cancer-advancing-non-invasive-detection-and-tailored-management/368999/",{"url":119,"name":65,"@type":121,"image":122,"author":127,"headline":65,"publisher":129,"fileFormat":132,"inLanguage":75,"description":66,"dateModified":133,"datePublished":134,"encodingFormat":132,"isAccessibleForFree":135,"interactionStatistic":136},"DigitalDocument",{"url":123,"@type":124,"width":125,"height":126},"https://docshare.wps.com/thumbnails/liquid-biopsy-and-circulating-biomarkers-in-head-and-neck-cancer-advancing-non-invasive-detection-and-tailored-management/368999.png","ImageObject",300,407,{"name":63,"@type":128},"Person",{"url":111,"name":130,"@type":131},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":137,"interactionType":138,"userInteractionCount":72},"InteractionCounter",{"@type":139},"ViewAction",{"@type":141,"mainEntity":142},"FAQPage",[143,149,153],{"name":144,"@type":145,"acceptedAnswer":146},"What is liquid biopsy used for in head and neck cancer?","Question",{"text":147,"@type":148},"Liquid biopsy is used to detect and monitor tumors through circulating biomarkers such as ctDNA, CTCs, cfRNA, miRNAs, extracellular vesicles, and viral nucleic acids, supporting applications in early detection, prognosis, and treatment guidance.","Answer",{"name":150,"@type":145,"acceptedAnswer":151},"Which biomarkers show the most clinical maturity according to the review?",{"text":152,"@type":148},"The review indicates that ctDNA and viral ctDNA are the most clinically mature biomarkers, with high sensitivity for minimal residual disease detection and the capacity to anticipate recurrence before imaging.",{"name":154,"@type":145,"acceptedAnswer":155},"What are the main barriers to routine clinical adoption?",{"text":156,"@type":148},"Key barriers include heterogeneity among studies, lack of assay standardization, and variable sensitivity thresholds, which limit widespread implementation until clinical validation and standardized protocols are established.","https://schema.org",{"og:url":119,"og:type":159,"og:title":65,"og:site_name":130,"og:description":66},"article",{"robots":161,"canonical":119},"index,follow",{"doc_id":61,"site_id":76},1790197743]